Boston Scientific’s $14.5bn Deal Folds Penumbra Thrombectomy Platforms Into Cardiovascular Franchise

Deal Adds High-Growth Thrombectomy Assets, Strengthens Competitive Position Versus Stryker And Medtronic

 
• By Shubham Singh
  
The deal, subject to shareholder approval but with expected closure later in 2026, comes just days after Boston struck a deal to acquire Valencia Technologies.

More from Deals

More from Business